

---

## Proact - Initiatives to Counter Cost Inflation

Redeye retains its positive view of Proact despite somewhat reducing our Base Case and 2023-2024 EBITA forecasts. Sales were solid in the quarter, with the highlight being 8% organic growth in recurring revenue. However, cost inflation hurt margins, which Proact has not yet fully compensated for, mostly due to its three years Cloud and Support contracts.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Proact - Initiatives to Counter Cost Inflation**